TECX
Tectonic Therapeutic, Inc.18.69
+0.30+1.63%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
349.81MP/E (TTM)
-Basic EPS (TTM)
-2.69Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Tectonic Therapeutic posted a Q3 operating loss of $21.9M, up 11% y/y from $19.6M (derived), driven by 18% higher R&D at $16.9M on TX2100 manufacturing and employee costs, offset by 7% lower G&A. Net loss narrowed to $19.0M from $17.7M y/y thanks to $2.9M interest income on bigger balances; diluted EPS improved to $(1.02) from $(1.20), confirmed against 18.7M shares. Cash swelled to $268.4M on $173.1M February private placement net proceeds, funding operations past 12 months. No debt beyond minor leases. Clinical delays loom from trial recruitment hurdles.
8-K
TX45 Phase 1b data shines
Tectonic Therapeutic reported Q3 2025 results, spotlighting positive TX45 Phase 1b Part B topline data: 29.2% PCWP reduction and 17.3% cardiac output boost in PH-HFrEF patients. Cash stands at $268.4M, funding ops into Q4'2028. TX45 APEX Phase 2 enrollment tops 50%; results due 2026. Pipeline expands with TX2100 Phase 1 and TX45 PH-ILD trials ahead.
8-K
Positive TX45 PH-HFrEF data
Tectonic Therapeutic released positive topline data from its Phase 1b Part B trial of TX45 in 14 PH-HFrEF patients on October 29, 2025. A single dose improved left heart function with PCWP down 29.2% and pulmonary hemodynamics including PVR reduced 19.7% in CpcPH patients, plus 17.3% higher cardiac output. Well-tolerated, no serious adverse events. Data bolsters PH-HFrEF expansion pending APEX Phase 2 results.
8-K
Q2 loss, strong cash, TX45 advances
Tectonic Therapeutic reported Q2 net loss of $20.0M, with R&D expenses up to $17.2M from clinical progress, yet cash at $287.4M funds operations into Q4 2028. TX45 Phase 1b Part A confirmed 19% PCWP drop and 18.5% cardiac output gain in PH-HFpEF; Part B enrollment done, results due early Q4 2025. Cash lasts through key readouts. Pipeline expands to PH-ILD Phase 2 in 2026.
10-Q
Q2 FY2025 results
Tectonic Therapeutic posted Q2 operating loss of $22.3M, up 96% y/y from $11.4M (derived), driven by R&D ramp to $17.2M on TX45 Phase 1b/2 trials and TX2100 preclinical work, while G&A rose 18% on stock comp. Net loss hit $20.0M or $(1.07) per share versus $12.7M or $(4.34) last year, narrowed by $3.4M interest income but widened by $1.0M tax on Aussie sub dissolution; EPS tracks 18.7M diluted shares. Cash swelled to $287M on $173M private placement, funding ops past 12 months, burn at $27.8M YTD. Solid runway. Clinical delays from trial enrollment or manufacturing snag key risks.
BCAX
Bicara Therapeutics Inc.
18.15-0.21
CMPX
Compass Therapeutics, Inc.
5.24+0.16
GRCE
Grace Therapeutics, Inc.
3.34+0.10
LEXX
Lexaria Bioscience Corp.
0.84-0.05
NKTR
Nektar Therapeutics
49.16-4.14
TCRX
TScan Therapeutics, Inc.
0.95-0.01
TLX
Telix Pharmaceuticals Limited
8.34-0.29
TNGX
Tango Therapeutics, Inc.
8.96-0.16
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75
XRTX
XORTX Therapeutics Inc.
0.59-0.01